Associated Papers
Kinase inhibitors in thyroid cancers.
Sukrithan V et al.
Endocrine Oncology (bristol, England), 2023
Molecular Characteristics of Repotrectinib That Enable Potent Inhibition of TRK Fusion Proteins and Resistant Mutations.
Murray BW et al.
Molecular Cancer Therapeutics, 2021
Select a paper to view details